Business Context and Reporting Period
Company: Orchestra BioMed Holdings, Inc. (OBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: October 24, 2025 (Events reported through October 28, 2025)
Business Overview: Orchestra BioMed is a clinical-stage medical device company focused on developing the Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) for the treatment of coronary artery disease and peripheral artery disease. The company is an emerging growth company.
Key Financial Metrics and Transactions
This filing details specific transactional events rather than periodic financial performance (revenue, profit, or cash flow statements are not included in this 8-K). Key financial figures disclosed include:
- ROFR Fee: $10 million payable by Terumo Medical Corporation (TMC) to Orchestra within 10 business days of the agreement date.
- Equity Investment: TMC agreed to purchase 200,000 shares of Series A Convertible Preferred Stock for gross proceeds of $20.0 million ($100.00 per share).
- Historical Payments: Orchestra previously received a $30 million non-refundable payment and a $5 million common stock investment from Terumo under the terminated Distribution Agreement.
- Debt and Liquidity: The filing does not provide current debt levels, cash balances, or liquidity metrics.
Material Changes Versus Prior Period
The filing reports significant strategic shifts regarding the company's commercialization strategy for Virtue SAB:
- Termination of Distribution Agreement: The Distribution Agreement with Terumo, dated June 13, 2019, was terminated effective October 24, 2025. Orchestra retains all rights to vascular indications outside of coronary artery disease (e.g., below-the-knee peripheral artery disease).
- Right of First Refusal (ROFR): Orchestra granted Terumo a ROFR regarding transactions involving Virtue SAB for coronary artery disease globally. This right is contingent on the $10 million fee and the equity investment.
- Clinical Trial Initiation: On October 27, 2025, the company announced the first patient enrollments in the Virtue SAB pivotal U.S. IDE trial (Virtue Trial) for coronary in-stent restenosis (ISR).
Guidance, Outlook, and Risks
Outlook and Milestones:
- ROFR Period: The ROFR term begins on the Effective Date and ends 90 days after Orchestra discloses primary endpoint data from its U.S. clinical trial for Virtue SAB, or upon Terumo's acquisition of a competing product.
- Clinical Trial Timeline: The Virtue Trial is expected to enroll 740 patients at up to 75 U.S. centers, with enrollment completion planned for mid-2027.
- Market Opportunity: Management estimates the total global market opportunity for drug-eluting balloons to be over $10 billion annually.
- Series A Preferred Stock: Convertible into Common Stock upon public disclosure of primary endpoint data and a stock price above $15.00, or upon a Change of Control. The conversion price is the greater of $12.00 or a 20% discount to the closing price.
- Lockup: Terumo is subject to a one-year lockup on its existing common stock holdings until October 24, 2026.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks related to regulatory approval, clinical trial timing, and competitive products.
- Transaction Contingency: The ROFR obligation is subject to Terumo paying the fee and the consummation of the Private Placement (Stock Purchase Agreement).
Investor Verification Checklist
- Verify the closing of the $20.0 million Series A Preferred Stock purchase by Terumo, expected by November 7, 2025.
- Confirm receipt of the $10 million ROFR Fee within 10 business days of October 24, 2025.
- Monitor the progress of the Virtue Trial enrollment (target: 740 patients) and the timeline for primary endpoint data disclosure, which triggers the ROFR expiration.
- Review the full terms of the Termination and ROFR Agreement (Exhibit 10.1) regarding the definition of "Competing Product" and the specific conditions for ROFR waiver.
- Assess the impact of the terminated Distribution Agreement on Orchestra's ability to commercialize Virtue SAB independently if Terumo does not exercise the ROFR.